|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Net loss from continuing operations | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation expense | |||||
| Amortization of intangible assets | |||||
| Change in fair value of warrant liability | |||||
| Change in fair value of derivative liability | |||||
| Options expense | |||||
| Loss on conversion of note payable | |||||
| Loss on disposition of subsidiaries | |||||
| Stock-based compensation | |||||
| Common stock issued for services | |||||
| Goodwill impairment | |||||
| Impairment of investment | |||||
| Amortization of debt discount | |||||
| Amortization of right-of-use assets | |||||
| Interest income | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, net | |||||
| Prepaid expenses and deposits | |||||
| Inventory | |||||
| Other receivables | |||||
| Right-of-use assets | |||||
| Lease liability | |||||
| Accounts payable | |||||
| Accrued liabilities | |||||
| Warrant liability | |||||
| Purchase price payable | |||||
| Current liabilities | |||||
| Net cash used in operating activities from continuing operations | |||||
| Net cash provided by (used in) operating activities from discontinued operations | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Cash received in acquisition | |||||
| Acquisition of property and equipment | |||||
| Investment in securities | |||||
| Funds acquired through acquisitions | |||||
| Net cash used in investing activities from continuing operations | |||||
| Net cash provided by investing activities from discontinued operations | |||||
| Net cash provided by investing activities | |||||
| Cash flows from financing activities: | |||||
| Repayment of contingent liability | |||||
| Proceeds from issuance from debt | |||||
| Repayment of debt | |||||
| Proceeds from loan payable, related party | |||||
| Repayment of loan payable, related party | |||||
| Proceeds from issuance of convertible notes, net of issuance costs | |||||
| Proceeds from convertible notes | |||||
| Repayment of convertible notes | |||||
| Gross proceeds from issuance of common stock | |||||
| Repayment of development liability | |||||
| Proceeds from sale of future revenue | |||||
| Proceeds from exercise of warrants | |||||
| Proceeds from securities purchase agreement | |||||
| Proceeds from exercise of options | |||||
| Net cash provided by (used in) financing activities from continuing operations | |||||
| Net cash used in financing activities from discontinued operations | |||||
| Net cash provided by (used in) financing activities | |||||
| Net change in cash | |||||
| Cash at beginning of period | |||||
| Cash at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for interest | |||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||
| Conversion of note payable into common stock | |||||
| Equity line of commitment shares issued as offering costs | |||||
| Issuance of note receivable in exchange for other receivables | |||||
| Issuance of shares pursuant to Merger | |||||
| Assets acquired in connection with Merger | |||||
| Liabilities assumed in connection with Merger | |||||
| Insurance premium financed | |||||
| Issuance of common shares in connection with converible debenture | |||||
| Deferred offering costs | |||||
| Derivative liability recognized in connection with issuance of convertible note | |||||
| Note issued as SOSRx contribution | |||||
| Not cancelled from SORx agreement termination | |||||
| Disposition of assets, related party | |||||
| Issuance of note receivable | |||||
| Warrants issued with convertible note | |||||
| Common stock issued for convertible note settlement | |||||
| Common stock issued for convertible note extension | |||||
| Accretion of original issue discount on Treasury Bills | |||||
Loading...